Related Experiment Video

Updated: Aug 16, 2026

Multi-Gene Single Nucleotide Polymorphism Detection in Gastric Cancer Based on Ion Semiconductor Sequencing Platform
06:21

Multi-Gene Single Nucleotide Polymorphism Detection in Gastric Cancer Based on Ion Semiconductor Sequencing Platform

Published on: May 10, 2024

Pharmacogenetics in gastrointestinal tumors

Jan Stöhlmacher1

  • 1Klinik und Polikinik für Innere Medizin I, Universitätsklinikum Carl Gustav Carus, TU Dresden, Deutschland. jan.stoehlmacher@uniklinikum-dresden.de

Onkologie
|September 15, 2005
PubMed

Insights

Genetic polymorphisms influence drug response in gastrointestinal cancers. Pharmacogenetics offers tailored therapy by analyzing gene variations for chemotherapy and targeted treatments, improving efficacy and reducing toxicity.

Area of Science:

  • Oncology
  • Pharmacogenetics
  • Gastrointestinal Cancer Treatment

Background:

  • Gastrointestinal cancer treatment has advanced with new drugs.
  • Individualizing therapy for maximum benefit and minimal toxicity remains a challenge.
  • Genetic variations (polymorphisms) significantly impact drug efficacy and toxicity.

Purpose of the Study:

  • To review clinically significant genetic polymorphisms in gastrointestinal cancer chemotherapy.
  • To discuss the role of pharmacogenetics in tailoring treatment for gastrointestinal cancers.
  • To explore pharmacogenetic applications in targeted therapies like cetuximab and bevacizumab.

Main Methods:

  • Review of literature on pharmacogenetics in gastrointestinal cancer.
  • Analysis of polymorphisms in genes metabolizing fluoropyrimidines, irinotecan, and platinum.
  • Examination of early pharmacogenetic findings for targeted agents (cetuximab, bevacizumab).

Main Results:

  • Clinically significant polymorphisms exist in genes affecting major chemotherapy drugs.
  • Pharmacogenetics shows promise for personalizing gastrointestinal cancer therapy.
  • Early data suggests pharmacogenetic relevance for targeted therapies.

Conclusions:

  • Pharmacogenetics is a valuable tool for designing tailored gastrointestinal cancer therapy.
  • Further large-scale, controlled studies are necessary to confirm and implement pharmacogenetic strategies.
  • Individualized treatment based on genetic profiles holds potential for improved patient outcomes.

More Related Videos

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down08:59

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down

Published on: December 11, 2017

Genome-Wide Analysis of DNA Methylation in Gastrointestinal Cancer07:50

Genome-Wide Analysis of DNA Methylation in Gastrointestinal Cancer

Published on: September 18, 2020

Related Concept Videos

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Pharmacogenetics and Pharmacogenomics: Overview01:29

Pharmacogenetics and Pharmacogenomics: Overview

Pharmacogenetics and pharmacogenomics examine how genetic factors influence an individual's response to drugs. While pharmacogenetics focuses on the impact of specific genetic variants on drug effects, pharmacogenomics takes a broader approach, studying how genetic variation across populations contributes to differences in drug responses. These fields aim to explain why individuals may experience varying levels of efficacy or adverse reactions to the same medication.Variability in drug...
Pharmacogenetics of Drug Metabolism: Overview01:27

Pharmacogenetics of Drug Metabolism: Overview

Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase01:27

Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase

Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...